Evercore ISI analyst Liisa Bayko upgraded Editas Medicine (EDIT) to Outperform from In Line with a price target of $7, up from $3. Editas has ...
In a report released today, Stephen Kim from Evercore ISI maintained a Buy rating on TopBuild (BLD – Research Report), with a price ...
Property and casualty insurers, as well as life insurers, are expected to benefit from Donald Trump's presidential election ...
Bloomberg on MSN16h
Harris Has 'Narrow' Path to Win Election, Evercore's Bianchi SaysSarah Bianchi, Evercore ISI chief strategist of political affairs and public policy, says some of the exit-poll data are ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback